Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, has published a new Spectrum report by John Ansell of John Ansell Consultancy on the current and future trends of new-product productivity in the pharmaceutical industry. Mr. Ansell maintains that for an average-sized top-20 pharmaceutical company (holding 3% share of the market) to be successful, it must produce just two new products every three years. The largest companies, such as Pfizer, will need to produce close to five new products each year.

"The number of products required to sustain different companies varies much more now than it did in the past. Therefore, what is required in terms of productivity should no longer be expressed as a 'one size fits all' target for all major companies," said John Ansell. "The target number of products must be tailored to each company."

"It is unlikely that enough new products will be generated over the next three to four years to ensure the survival of all major pharmaceutical companies as independent entities. Beyond 2007, however, industry pipeline projections suggest a return to high levels of productivity that will enable the majority of surviving companies to prosper," continued Mr. Ansell.

Decision Resources has organized a teleconference for those interested in hearing more about Mr. Ansell's findings on the new-product need in the pharmaceutical industry. The teleconference will be on Tuesday, September 30, at 10:00 a.m. EST. For more information about the teleconference or to sign up to participate, please contact:

  For media:    Liz Marshall, Decision Resources, 781-296-2563   For other interested parties:    Frank Sama, Decision Resources, 781-296-2553    About Spectrum from Decision Resources 

Spectrum is a comprehensive executive advisory service that identifies and analyzes key business and technology drivers of the pharmaceutical and biotechnology markets. A mix of publications, telephone inquiry access, and teleconferences provides an "over the horizon" perspective for decision makers wrestling with complex issues and opportunities. Spectrum's analysis and research is organized into the following report portfolios:

  * Pharmaceutical Industry Dynamics   * Therapy Markets and Emerging Technologies   * Diagnostics and Related Technologies   * Pharmacoeconomics, Pricing, and Reimbursement   * Drug Discovery and Design   * Drug Delivery and Reformulation Technologies    About Decision Resources 

Decision Resources is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  FOR MORE INFORMATION, CONTACT:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-

Drug Market for Type 2 Diabetes Will Reach $20.5 Billion in 2012

View Now